Mathurin Fumery (M Fumery)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 31

Top Topics

Ulcerative Colitis

Top Venues

Alimentary pharmacology & therapeutics

Journal of Crohn's & colitis

Expert review of clinical immunology

This page only lists publications with an associated author ORCID identifier.

Publications

Maria Manuela Estevinho, Vishal Midya, Shirley Cohen-Mekelburg, Kristine Højgaard Allin, Mathurin Fumery, Salome S Pinho, Jean Frederic Colombel, Manasi Agrawal
Emerging role of environmental pollutants in inflammatory bowel disease risk, outcomes and underlying mechanisms. Gut (2024)
David Laharie, Lucine Vuitton, Arnaud Bourreille, Yoram Bouhnik, Jean-Frédéric Colombel, Edouard Louis, Mathurin Fumery, Charlotte Mailhat, Jean-Yves Mary, Laurent Peyrin-Biroulet
The GETAID: 40 years of a family story in IBD. Journal of Crohn's & colitis (2024)
Mathurin Fumery, Mélanie Serrero, Guillaume Bouguen, Aurélien Amiot, Romain Altwegg, Maria Nachury, Lucine Vuitton, Xavier Treton, Ludovic Caillo, Bruno Pereira, Antony Buisson
Real-world comparison of the effectiveness between ustekinumab and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent. Journal of Crohn's & colitis (2024)
Pascal Petit, Ariane Leroyer, Sylvain Chamot, Mathurin Fumery, Vincent Bonneterre
Farming Activities and Risk of Inflammatory Bowel Disease: A French Nationwide Population-based Cohort Study. Journal of Crohn's & colitis 18 (9) (2024)
Maria Manuela Estevinho, Vishal Midya, Shirley Cohen-Mekelburg, Kristine Højgaard Allin, Mathurin Fumery, Salome Pinho, Jean Frederic Colombel, Manasi Agrawal
Emerging role of environmental pollutants in inflammatory bowel disease risk, outcomes and underlying mechanisms. Gut (2024)
Maria Manuela Estevinho, Vishal Midya, Shirley Cohen-Mekelburg, Kristine Højgaard Allin, Mathurin Fumery, Salome Pinho, Jean Frederic Colombel, Manasi Agrawal
Emerging role of environmental pollutants in inflammatory bowel disease risk, outcomes and underlying mechanisms. Gut (2024)
Pascal Petit, Ariane Leroyer, Sylvain Chamot, Mathurin Fumery, Vincent Bonneterre
Farming activities and risk of inflammatory bowel disease: a French nationwide population-based cohort study. Journal of Crohn's & colitis (2024)
Hélène Sarter, Guillaume Savoye, Guillemette Marot, Delphine Ley, Dominique Turck, Jean-Pierre Hugot, Francis Vasseur, Alain Duhamel, Pauline Wils, Fred Princen, Jean-Frédéric Colombel, Corinne Gower-Rousseau, Mathurin Fumery, null null
A Novel 8-Predictors Signature to Predict Complicated Disease Course in Pediatric-onset Crohn's Disease: A Population-based Study. Inflammatory bowel diseases (2023)
Anthony Buisson, M Nachury, M Bazoge, C Yzet, P Wils, M Dodel, D Coban, B Pereira, Mathurin Fumery
Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study. Alimentary pharmacology & therapeutics (2023)
Mathurin Fumery, Xavier Roblin
Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring-author's reply. Alimentary pharmacology & therapeutics 57 (12) (2023)
Mathieu Uzzan, Maria Nachury, Alexandre Nuzzo, Aurélien Amiot, Bénédicte Caron, Alban Benezech, Anthony Buisson, Guillaume Bouguen, Catherine Le Berre, Catherine Reenaers, Guillaume Le Cosquer, Guillaume Savoye, Maeva Charkaoui, Mathias Vidon, Lucas Guillo, Mathurin Fumery, Laurent Peyrin-Biroulet, Julien Kirchgesner, Yoram Bouhnik, null null
Tofacitinib for patients with anti-TNF refractory ulcerative proctitis: a multicenter cohort study from the GETAID. Journal of Crohn's & colitis (2023)
Mathurin Fumery, Laurent Peyrin Biroulet
Editorial: risankizumab - ready to break ceilings? author's reply. Alimentary pharmacology & therapeutics 57 (8) (2023)
Nicolas Richard, Lucine Vuitton, Mathurin Fumery
Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in patients with inflammatory bowel disease. Alimentary pharmacology & therapeutics 57 (6) (2023)
Philip J Smith, Mathurin Fumery, Rupert W L Leong, Kerri L Novak, Axel U Dignass
Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease. Expert review of clinical immunology (2023)
Mathurin Fumery, Stéphane Nancey, Jérôme Filippi, Romain Altwegg, Xavier Hébuterne, Gilles Boshetti, Mathilde Barraud, Jonathan Meynier, Stéphane Paul, Xavier Roblin
Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study. Alimentary pharmacology & therapeutics (2023)
Anthony Buisson, Emilie Vazeille, Mathurin Fumery, Benjamin Pariente, Stéphane Nancey, Philippe Seksik, Laurent Peyrin-Biroulet, Matthieu Allez, Nathalie Ballet, Jérôme Filippi, Clara Yzet, Maria Nachury, Gilles Boschetti, Elisabeth Billard, Anaëlle Dubois, Stéphanie Rodriguez, Caroline Chevarin, Marion Goutte, Gilles Bommelaer, Bruno Pereira, Xavier Hebuterne, Nicolas Barnich, null null
Faster and less invasive tools to identify patients with ileal colonization by adherent-invasive E. coli in Crohn's disease. United European gastroenterology journal 9 (9) (2022)
Bénédicte Caron, Mathurin Fumery, Patrick Netter, Laurent Peyrin Biroulet
Letter: treatment with subcutaneous CT-P13 in Crohn's disease patients with intravenous infliximab failure. Alimentary pharmacology & therapeutics 55 (4) (2022)
Mathurin Fumery, Antoine Defrance, Xavier Roblin, Romain Altwegg, Benedicte Caron, Xavier Hébuterne, Carmen Stefanescu, Antoine Meyer, Maria Nachury, David Laharie, Stephane Nancey, Catherine Le Berre, Melanie Serrero, Sophie Geyl, Cyrielle Giletta, Philippe Ah-Soune, Nicolas Duveau, Mathieu Uzzan, Vered Abitbol, Amelie Biron, My-Linh Tran-Minh, Thierry Paupard, Lucine Vuitton, Yasmine Elgharabawy, Laurent Peyrin Biroulet
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study. Alimentary pharmacology & therapeutics 57 (4) (2022)
Mathurin Fumery, Antoine Defrance, Xavier Roblin, Romain Altwegg, Benedicte Caron, Xavier Hébuterne, Carmen Stefanescu, Antoine Meyer, Maria Nachury, David Laharie, Stephane Nancey, Catherine Le Berre, Melanie Serrero, Sophie Geyl, Cyrielle Giletta, Philippe Ah-Soune, Nicolas Duveau, Mathieu Uzzan, Vered Abitbol, Amelie Biron, My-Linh Tran-Minh, Thierry Paupard, Lucine Vuitton, Yasmine Elgharabawy, Laurent Peyrin Biroulet
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study. Alimentary pharmacology & therapeutics (2022)
Anthony Buisson, Maria Nachury, Thomas Guilmoteau, Romain Altwegg, Xavier Treton, Mathurin Fumery, Melanie Serrero, Eloïse Leclerc, Ludovic Caillo, Bruno Pereira, Aurélien Amiot, Guillaume Bouguen
Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent. Alimentary pharmacology & therapeutics (2022)
Mathurin Fumery, Antoine Defrance, Xavier Roblin, Romain Altwegg, Benedicte Caron, Xavier Hébuterne, Carmen Stefanescu, Antoine Meyer, Maria Nachury, David Laharie, Stephane Nancey, Catherine Le Berre, Melanie Serrero, Sophie Geyl, Cyrielle Giletta, Philippe Ah-Soune, Nicolas Duveau, Mathieu Uzzan, Vered Abitbol, Amelie Biron, My-Linh Tran-Minh, Thierry Paupard, Lucine Vuitton, Yasmine Elgharabawy, Laurent Peyrin Biroulet
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study. Alimentary pharmacology & therapeutics 57 (4) (2022)
Mathurin Fumery, Jérôme Filippi, Vered Abitbol, Amélie Biron, David Laharie, Melanie Serrero, Romain Altwegg, Yoram Bouhnik, Laurent Peyrin Biroulet, Cyrielle Gilletta, Xavier Roblin, Guillaume Pineton de Chambrun, Lucine Vuitton, Anne Bourrier, Stephane Nancey, Jean-Marc Gornet, Stephane Nahon, Guillaume Bouguen, Stephanie Viennot, Maria Nachury, Aurélien Amiot
Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. Alimentary pharmacology & therapeutics 54 (7) (2021)
Doriane Broussard, Pauline Riviere, Joelle Bonnet, Ginette Fotsing, Aurélien Amiot, Laurent Peyrin Biroulet, Sylvie Rajca, Anthony Buisson, Cyrielle Gilleta, Anne-Laure Pelletier, Melanie Serrero, Guillaume Bouguen, Romain Altwegg, Xavier Hebuterne, Stephane Nancey, Mathurin Fumery, Guillaume Cadiot, Stephane Nahon, Jean-Francois Rahier, Jean-Marc Gornet, Veronique Vendrely, David Laharie, null null
Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID. Alimentary pharmacology & therapeutics 53 (3) (2020)
Pauline Wils, Philippe Seksik, Carmen Stefanescu, Stephane Nancey, Matthieu Allez, Guillaume Pineton de Chambrun, Romain Altwegg, Cyrielle Gilletta, Lucine Vuitton, Stéphanie Viennot, Mélanie Serrero, Mathurin Fumery, Guillaume Savoye, Michael Collins, Felix Goutorbe, Hedia Brixi, Guillaume Bouguen, Noémie Tavernier, Medina Boualit, Aurélien Amiot, Vered Abitbol, David Laharie, Benjamin Pariente, null null
Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study. Alimentary pharmacology & therapeutics 53 (4) (2020)
Marianne Hupé, Pauline Riviere, Stephane Nancey, Xavier Roblin, Romain Altwegg, Jerome Filippi, Mathurin Fumery, Guillaume Bouguen, Laurent Peyrin Biroulet, Arnaud Bourreille, Ludovic Caillo, Mireille Simon, Felix Goutorbe, David Laharie
Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. Alimentary pharmacology & therapeutics 51 (9) (2020)
Constance Chapuis-Biron, Anne Bourrier, Maria Nachury, Stéphane Nancey, Yoram Bouhnik, Mélanie Serrero, Laura Armengol-Debeir, Anthony Buisson, My-Linh Tran-Minh, Camille Zallot, Mathurin Fumery, Guillaume Bouguen, Vered Abitbol, Stéphanie Viennot, Elise Chanteloup, Sylvie Rajca, Nina Dib, Anne-Laure Parmentier, Laurent Peyrin Biroulet, Lucine Vuitton, null null
Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients. Alimentary pharmacology & therapeutics 51 (7) (2020)
Mathurin Fumery, Clara Yzet, Franck Brazier
Letter: combination of biologics in inflammatory bowel diseases. Alimentary pharmacology & therapeutics 52 (3) (2020)
Aurélien Amiot, Jérôme Filippi, Vered Abitbol, Guillaume Cadiot, David Laharie, Melanie Serrero, Romain Altwegg, Yoram Bouhnik, Laurent Peyrin Biroulet, Cyrielle Gilletta, Xavier Roblin, Guillaume Pineton de Chambrun, Lucine Vuitton, Anne Bourrier, Stephane Nancey, Jean-Marc Gornet, Stephane Nahon, Guillaume Bouguen, Stephanie Viennot, Benjamin Pariente, Mathurin Fumery, null null
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. Alimentary pharmacology & therapeutics 51 (11) (2020)
Aurélien Amiot, Melanie Serrero, Laurent Peyrin Biroulet, Jerome Filippi, Benjamin Pariente, Xavier Roblin, Anthony Buisson, Carmen Stefanescu, Caroline Trang-Poisson, Romain Altwegg, Philippe Marteau, Thibaud Vaysse, Anne Bourrier, Stephane Nancey, David Laharie, Matthieu Allez, Guillaume Savoye, Jacques Moreau, Lucine Vuitton, Stephanie Viennot, Guillaume Bouguen, Vered Abitbol, Mathurin Fumery, Charlotte Gagniere, Yoram Bouhnik, null null
Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. Alimentary pharmacology & therapeutics 50 (1) (2019)
Siddharth Singh, Parambir S Dulai, Niels Vande Casteele, Robert Battat, Mathurin Fumery, Brigid S Boland, William J Sandborn
Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. Alimentary pharmacology & therapeutics 50 (8) (2019)
Michael Génin, Mathurin Fumery, Florent Occelli, Guillaume Savoye, Benjamin Pariente, Luc Dauchet, Jonathan Giovannelli, Cécile Vignal, Mathilde Body-Malapel, Hélène Sarter, Corinne Gower-Rousseau, Grégoire Ficheur
Fine-scale geographical distribution and ecological risk factors for Crohn's disease in France (2007-2014). Alimentary pharmacology & therapeutics 51 (1) (2019)